Anakim Sherman

Anakim Sherman

Auto-generated profile, based on publicly available information

Anakim Sherman

City of Hope Beckman Research Institute

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2019 in Journal of Biomedical Optics
Verified
Journal Article
Open access
PDF file
PYPaul J. Yazaki
Paul J. Yazaki
Thinzar LwinThinzar Lwin
Thinzar Lwin
MMMegan Minnix
Megan Minnix
LLLin Li
Lin Li
ASAnakim Sherman
Anakim Sherman
Michael BouvetMichael Bouvet
Michael Bouvet
Fluorescence-guided surgery (FGS) using tumor-specific antibodies conjugated with near-infrared fluorophores (NIR) have demonstrated the potential to visualize solid tumor lesions in preclinical and early stage clinical trials.1 – 3 Several commercial cancer therapeutic monoclonal antibodies (mAbs) have been repurposed as molecular optical imaging agents by their conjugation with NIR dyes and are in early-stage clinical trials.4 – 6 Compared to visible light fluorophores, NIR fluorophores have reduced light scattering, increased depth of penetration, and minimal autofluorescence. The use of NIR dyes in the 800-nm range enables the use of instrumentation available in most operating suites using the FDA-approved indocyanine green dye to monitor cardiac output and liver blood flow function. Our theranostics group has focused on the development of anti-carcinoembryonic antigen (CEA) mAbs for the radionuclide imaging and therapy of CEA-positive disease.7 – 12 CEA is surface GPI-linked glycoprotein highly expressed in gastrointestinal malignancies (GI), such as colorectal (95%), gastric (80%), pancreatic (60%), and breast (50%) cancers but with very limited expression in normal adults.13 – 17 We designed and produced a recombinant humanized anti-CEA hT84.66-M5A (M5A) mAb that is currently in early phase clinical trials.18 Radiolabeled with the positron emission tomography (PET) radionuclide Cu-64, the Cu64-DOTA-M5A mAb has provided promising PET images of CEA-positive disease in an ongoing pilot imaging trial (NCT02293954). Based on success with immunoPET imaging prior to surgery, a natural extension of the anti-CEA M5A mAb would be its development for fluorescent image-guided surgery. We have collaborated with the Bouvet group who have a long-standing expertise on the preclinical use of a chimeric anti-CEA antibody for FGS.19 – 23 Using the commercial NHS-IRDye800CW currently being used in antibody-targeted FGS clinical trials,5,24 the M5A-IR800 exhibited strong tumor-specific labeling in a human colon cancer25 as well as pancreatic cancer26 orthotopic xenograft mouse models. However, these studies identified room for improvement, in that conjugation of the IRDye800CW fluorophore to M5A resulted in accelerated pharmacokinetics over the unmodified M5A mAb, requiring low antibody-to-dye ratios, limiting sensitivity of tumor detection over a shortened window for surgical planning.